rs121913322
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs121964872
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
rs1271572
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Compared to homozygous common allele carriers, homozygous carriers of variant alleles for rs1271572 [odds ratio (OR) = 1.79, 95% confidence interval (CI):1.15-2.79, p global = 0.01] and rs1256030 [OR = 1.67, CI: 1.08-2.59, p global = 0.04], and women with haplotypes, including variant alleles of rs1271572, rs1256030, and rs1256031 SNPs [OR = 1.75, CI: 1.17-2.63, p global = 0.007], had significantly increased risk of ovarian carcinoma.
|
18704709 |
2009 |
rs1256030
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Compared to homozygous common allele carriers, homozygous carriers of variant alleles for rs1271572 [odds ratio (OR) = 1.79, 95% confidence interval (CI):1.15-2.79, p global = 0.01] and rs1256030 [OR = 1.67, CI: 1.08-2.59, p global = 0.04], and women with haplotypes, including variant alleles of rs1271572, rs1256030, and rs1256031 SNPs [OR = 1.75, CI: 1.17-2.63, p global = 0.007], had significantly increased risk of ovarian carcinoma.
|
18704709 |
2009 |
rs1256031
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Compared to homozygous common allele carriers, homozygous carriers of variant alleles for rs1271572 [odds ratio (OR) = 1.79, 95% confidence interval (CI):1.15-2.79, p global = 0.01] and rs1256030 [OR = 1.67, CI: 1.08-2.59, p global = 0.04], and women with haplotypes, including variant alleles of rs1271572, rs1256030, and rs1256031 SNPs [OR = 1.75, CI: 1.17-2.63, p global = 0.007], had significantly increased risk of ovarian carcinoma.
|
18704709 |
2009 |
rs80358721
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation.
|
19654294 |
2009 |
rs495139
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Biomarkers that distinguish ovarian carcinoma types are few, and TYMS rs495139 may provide a novel clue to type etiology.
|
20570913 |
2010 |
rs5275
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies.
|
20559705 |
2010 |
rs1271572
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.
|
21673961 |
2011 |
rs2073495
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we determined the distribution of LTF gene polymorphisms (rs1126477, rs1126478, rs2073495, and rs9110) in the Chinese Han population and investigated whether these polymorphisms were associated with increased risk of ovarian carcinoma in the Chinese.
|
21937479 |
2011 |
rs9110
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we determined the distribution of LTF gene polymorphisms (rs1126477, rs1126478, rs2073495, and rs9110) in the Chinese Han population and investigated whether these polymorphisms were associated with increased risk of ovarian carcinoma in the Chinese.
|
21937479 |
2011 |
rs25487
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Impact of RAD51 G135C and XRCC1 Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women.
|
26406958 |
2015 |
rs185229225
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.
|
27047539 |
2016 |
rs3218536
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The obtained results indicate that XRCC2 Arg188His and XRCC3 Thr241Met polymorphisms may be positively associated with the incidence of ovarian carcinoma in the population of Polish women.
|
26801223 |
2016 |
rs861539
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The obtained results indicate that XRCC2 Arg188His and XRCC3 Thr241Met polymorphisms may be positively associated with the incidence of ovarian carcinoma in the population of Polish women.
|
26801223 |
2016 |
rs238406
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The R156R (C to A, rs238406) polymorphism of ERCC2 gene was investigated by the PCR-RFLP technique in 400 patients with ovarian carcinoma and 400 age- and sex matched non-cancer controls.
|
27888704 |
2017 |
rs495139
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (<i>r</i> = 0.51, <i>p</i> = 1.7 × 10<sup>-28</sup>), and nonsignificantly in five MOC tumors.
|
30134598 |
2018 |
rs121434596
|
|
|
0.010 |
GeneticVariation |
BEFREE |
NRAS mutation in codon 13 (G13D, p.Gly13Asp; nucleotide: c.38G>A) was found in one patient, a woman with low-grade serous ovarian carcinoma.
|
29682098 |
2018 |
rs1799950
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further characterisation of rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
|
29298688 |
2018 |